StockData
BeOne Medicines Ltd. logo

BeOne Medicines Ltd. (ONC) operating KPIs

ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$370.33−1.23 (-0.33%)

Close on Oct 30, 2026Market cap $42.11BP/E 66.2Yield –

BeOne Medicines collaboration R&D Cost Reimbursement Revenue ($M, FY16–FY21) ($M)

Form 10-Q / 10-K Collaboration Note

Latest, Q4 2020
0
Period ended Dec 31, 2020
Change on a year earlier
–
0 in Q4 2019
History
14 quarters
Since Q3 2017
Sources
9
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCollaboration R&D Cost Reimbursement Revenue ($M, FY16–FY21) ($M)Year on yearSource
Q4 2020Dec 31, 20200–Form 10-K (filed 2022-02-28) ↗
Q3 2020Sep 30, 20200–Form 10-Q (filed 2020-11-05) ↗
Q2 2020Jun 30, 20200-100.0%Form 10-Q (filed 2020-08-06) ↗
Q1 2020Mar 31, 20200-100.0%Form 10-Q (filed 2020-05-11) ↗
Q4 2019Dec 31, 20190-100.0%Form 10-K (filed 2022-02-28) ↗
Q3 2019Sep 30, 20190-100.0%Form 10-Q (filed 2020-11-05) ↗
Q2 2019Jun 30, 20199.50-47.8%Form 10-Q (filed 2020-08-06) ↗
Q1 2019Mar 31, 201918.2+142.7%Form 10-Q (filed 2019-05-09) ↗
Q4 2018Dec 31, 201817.5–Form 10-K (filed 2021-02-25) ↗
Q3 2018Sep 30, 201813.5–Form 10-Q (filed 2018-11-08) ↗
Q2 2018Jun 30, 201818.2–Form 10-Q (filed 2018-08-09) ↗
Q1 2018Mar 31, 20187.50–Form 10-Q (filed 2019-05-09) ↗
Q4 2017Dec 31, 20170–Form 10-K (filed 2020-03-02) ↗
Q3 2017Sep 30, 20170–Form 10-Q (filed 2018-11-08) ↗

Cite this data

StockData. (2026). BeOne Medicines Collaboration R&D Cost Reimbursement Revenue ($M, FY16–FY21) ($M), quarterly Q3 2017–Q4 2020 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/rev_collab_rd_reimb

See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.